Cover Image
市場調查報告書

靜脈血栓栓塞症 (VTE) :主要24個市場預測

Epiomic Epidemiology Series: Venous Thromboembolism Forecast in 24 Major Markets 2018-2028

出版商 Black Swan Analysis 商品編碼 667520
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
靜脈血栓栓塞症 (VTE) :主要24個市場預測 Epiomic Epidemiology Series: Venous Thromboembolism Forecast in 24 Major Markets 2018-2028
出版日期: 2018年08月01日 內容資訊: 英文 78 Pages
簡介

本報告提供靜脈血栓栓塞症 (VTE)的罹患情形全球主要24個國家的調查,患病人數的變化與預測,各國家、年齡層、性別、疾病種類的明細,疾病概要,危險因素,疾病診斷與預後,主要的症狀和並存症等彙整資料。

調查對象國家

  • 美國
  • 加拿大
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 波蘭
  • 挪威
  • 瑞典
  • 丹麥
  • 芬蘭
  • 奧地利
  • 葡萄牙
  • 希臘
  • 土耳其
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 阿根廷

目錄

  • 圖表
  • 簡介
  • 病因
  • 危險因素和預防
  • 疾病診斷
  • 變異:各地區/民族
  • 疾病預後和臨床過程
  • 疾病相關的主要併發症/特徵
  • 定量化患者數的手法
  • 靜脈血栓栓塞症 (VTE)的最大患病人數
  • 深部靜脈血栓症 (DVT)
  • 肺動脈栓塞 (PE)
  • 靜脈血栓栓塞症 (VTE) 患者的合併症
  • 簡稱
  • 其他服務、解決方案
  • 報告、出版物
  • 線上流行病學資料庫
  • 線上藥價資料庫
  • 參考文獻
  • 附錄
目錄
Product Code: VTHR0010818

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Venous Thromboembolism in 24 Major Markets

Venous thromboembolism (VTE) is a disease in which thrombi or blood clots form in venous blood vessels and either remain at their site of origin or move with the blood flow until they reach a vessel with a diameter small enough to form an occlusion. Clots formed in the large limb or pelvic veins cause a clinical manifestation of VTE called deep vein thrombosis (DVT), while emboli (detached clot fragments) which move to and cause obstruction of pulmonary blood vessels cause a pulmonary embolism (PE). VTE is the third most common cardiovascular disease worldwide (after myocardial infarction and ischaemic stroke), with 2-5% of the global population affected throughout their lives.

This report provides the current prevalent population for VTE across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Norway, Sweden, Denmark, Finland, Austria, Portugal, Greece, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, DVT and PE patient subsets, as well as those with the main co-morbidities, have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for VTE include:

  • Cancer
  • Inflammatory bowel disease
  • Obesity
  • Cardiovascular diseases

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global VTE market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of VTE and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding on the impact of specific co-morbid conditions on the prevalent population of VTE patients.
  • Identification of VTE patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of VTE patients.

Table of Contents

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR VENOUS THROMBOEMBOLISM
  • DEEP VEIN THROMBOSIS
  • PULMONARY EMBOLISM
  • COMORBIDITIES OF VENOUS THROMBOEMBOLISM PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. VTE risk factors
  • Table 2. Prevalence of VTE, total (000s)
  • Table 3. Prevalence of VTE, males (000s)
  • Table 4. Prevalence of VTE, females (000s)
  • Table 5. Prevalence of DVT, total (000s)
  • Table 6. Prevalence of DVT, males (000s)
  • Table 7. Prevalence of DVT, females (000s)
  • Table 8. Prevalence of PE, total (000s)
  • Table 9. Prevalence of PE, males (000s)
  • Table 10. Prevalence of PE, females (000s)
  • Table 11. VTE patients with post-thrombotic syndrome, total (000s)
  • Table 12. VTE patients with venous ulcers, total (000s)
  • Table 13. VTE patients with major bleeding from prophylaxis, total (000s)
  • Table 14. PE patients with chronic thromboembolic pulmonary hypertension, total (000s)
  • Table 15. Abbreviations and acronyms used in the report
  • Table 16. USA prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 17. USA prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 18. Canada prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 19. Canada prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 20. France prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 21. France prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 22. Germany prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 23. Germany prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 24. Italy prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 25. Italy prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 26. Spain prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 27. Spain prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 28. UK prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 29. UK prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 30. Poland prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 31. Poland prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 32. Norway prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 33. Norway prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 34. Sweden prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 35. Sweden prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 36. Denmark prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 37. Denmark prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 38. Finland prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 39. Finland prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 40. Austria prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 41. Austria prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 42. Portugal prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 43. Portugal prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 44. Greece prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 45. Greece prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 46. Turkey prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 47. Turkey prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 48. Japan prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 49. Japan prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 50. China prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 51. China prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 52. South Korea prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 53. South Korea prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 54. India prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 55. India prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 56. Australia prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 57. Australia prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 58. Brazil prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 59. Brazil prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 60. Mexico prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 61. Mexico prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
  • Table 62. Argentina prevalence of venous thromboembolism by 5-yr age cohort, males (000s)
  • Table 63. Argentina prevalence of venous thromboembolism by 5-yr age cohort, females (000s)
Back to Top